MC3 Cardiopulmonary completes acquisition of Terumo’s surgical cannula line

4 November 2015 (Last Updated November 4th, 2015 18:30)

US-based medical device firm MC3 Cardiopulmonary has completed the acquisition of surgical cannula product assets from Terumo Cardiovascular.

Terumo

US-based medical device firm MC3 Cardiopulmonary has completed the acquisition of surgical cannula product assets from Terumo Cardiovascular.

Under the deal, MC3 acquired Terumo's previously marketed Surgical Cannula line, which includes brands such as Sarns Soft-Flow arterial cannula.

The Terumo surgical cannula line, which is claimed to be one of the largest cardiac surgery cannula lines worldwide, includes 200 product stock keeping units (SKUs).

The company noted the Soft-Flow arterial cannula is the world's first dispersion tip aortic cannula designed for clinical users.

MC3 developed a 60,000ft² manufacturing facility on its ten acre campus in Dexter, Michigan, to support production of Soft-Flow arterial cannula, which is expected during the first half of next year.

The acquisition is part of the company's aim to transform into a global cardiopulmonary medical device manufacturer.

"This is a significant milestone for us, and we are excited to return the legacy of Soft-Flow arterial cannula to the users and patients it will serve."

MC3 Cardiopulmonary CEO Scott Merz said: "This is a significant milestone for us, and we are excited to return the legacy of Soft-Flow arterial cannula to the users and patients it will serve.

"In order to support our goals as a global medical device company, we have built a world-class facility just outside of Ann Arbor in Dexter, Michigan.

"The location provides close proximity to the University of Michigan, Detroit International Airport and skilled knowhow within our sector."

Established in 1991 as a spinout of the University of Michigan (UMich), MC3 develops medical devices to meet acute and chronic cardiopulmonary clinical needs.

The company was founded with the aim of commercialising intellectual property related to artificial heart and lung technologies from UMich.

The company is currently focused on becoming a leading medical device developer and manufacturer in the cardiopulmonary device community. It has expertise in patient physiology, hemodynamics, technology and caregiver needs.


Image: MC3's new manufacturing facility at Dexter. Photo: courtesy of MC3 Cardiopulmonary.